Biogen, TheraPanacea to develop digital health solutions in neurology

Biogen Inc. and TheraPanacea announced a collaboration to use machine learning and artificial intelligence analysis to develop digital health solutions for neurological diseases, according to a company press release.

“Advancements in technology may increase our ability to understand disease, target treatments and manage risk,” Martin Dubuc, head of Biogen Digital Health, said in the release. “Based on the outcome of our prior work with TheraPanacea and their success with AI in oncology, we are excited to further this collaboration. We believe digital health solutions will enable us to pioneer a new era of personalized medicine built upon a foundation of accessibility and precision.”

The collaborators seek to improve patient care, accelerate drug development and provide insights into the underlying pathologies of neurological diseases with digital health solutions. The combination of machine learning (ML) and AI may allow for the derivation of meaning from medical imaging and other clinically relevant data sources and thus provide an avenue for improving disease understanding and enabling expanded personalization of clinical trial design, according to the release. These advancements may thus lead to shortened drug development cycles, lowered related costs and increased probability of success.

“We are excited to collaborate with Biogen and combine our ML and AI solutions with their world-class clinical expertise and unique datasets in neuroscience,” Nikos Paragios, CEO of TheraPanacea and distinguished professor of mathematics at CentraleSupélec, University of Paris-Saclay, said in the release. “Through this collaboration, we aim to scale our artificial intelligence multi-omics biomarker discovery platform and deploy clinical solutions that have the potential to deliver better treatment decisions for patients living with neurological diseases.”